BAL0891tislelizumabTTK-CS-101paclitaxelTTK-CS-001triple-negative breast cancer
… tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of BAL0891 monotherapy and combination with paclitaxel.Trial Registration …
1articles mentioning drugs
1drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: TTK-CS-001 ×
TTK-CS-001
This drug is selected. Its supporting articles are shown below.